Comparative study of the effect of ace-inhibitors and other antihypertensive agents on proteinuria in diabetic patients

American Journal of Hypertension

Volumn 7, Issue 9, 1994, Pages 84S-92S

  Böhlen, Lorenz ^a   Courten, Maximilian De ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Angiotensin converting enzyme inhibitors; Calcium antagonists; Glomerular filtration rate; Microalbuminuria; Overt proteinuria

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NIFEDIPINE;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; PROTEINURIA; STATISTICAL ANALYSIS;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COMPARATIVE STUDY; DIABETES MELLITUS; GLOMERULAR FILTRATION RATE; HUMAN; PROTEINURIA;

EID: 0027943767     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/7.9.84S     Document Type: Article

References (92)

1. United States Renal Data System: USRDS 1990 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institutes of Diabetes and Digestive Diseases, 1990.
2. Centers for Disease Control: End-stage renal disease associated with diabetes. United States 1988. MMWR 1989;38:546–548.
3. Viberti GC: Microalbuminuria as a predictor of clinical nephropathy in insulin dependent diabetes mellitus. Lancet 1982;i:1430–1432.
4. Mattock MB, Morrish NJ, Viberti GC, et al: Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41:736–741.
5. Mogensen CE, Hansen KW: Preventing and postponing renal disease in insulin-dependent diabetes by glycemic and nonglycemic intervention. Contrib Nephrol 1990;78:73–100.
6. Krolewsky AS, Warram JH, Christlieb AR, et al: The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785–794.
7. Parving HH, Hommel E: Prognosis in diabetic nephropathy. Br Med J 1989;299:230–233.
8. Viberti GC, Yip-Messent J, Morocutti A: Diabetic nephropathy. Diabetes Care 1992;15:1216–1225.
9. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al: Natural history of diabetic complications: early detection and progression. Diabetic Med 1991;8(Symposium):S33–S37.
10. Hasslacher C, Wolf rum M, Stech G, et al: Diabetische Nephropathie bei Typ-II-Diabetes. Dtsch Med Wschr 1987;112:1445–1449.
11. Nelson RG, Pettitt DJ, Baird HR, et al: Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1993;36:998–1001.
12. Morrish NJ, Stevens LK, Head J, et al: A prospective study on mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics). II: associated risk factors. Diabetologia 1990;33:542–548.
13. Wilson PW, Cupples LA, Kannel WB: Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991;121(2 Pt 1):586–590.
14. Borch-Johnsen K, Kreiner S: Proteinuria: value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987;294:1651–1654.
15. Zeller K, Whittaker E, Sullivan L, et al: Effect of restricting dietary protein on the progression of renal failure in patients with insulin/dependent diabetes mellitus. N Engl J Med 1991;324:78–83.
16. Christiansen CK, Mogensen CE: Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 1985;7(suppl 2):109–113.
17. Parving HH, Andersen AR, Smidt UM, et al: Effects of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987;294:1443–1447.
18. Parving HH, Hommel E, Smidt UM: Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988;297:1086–1091.
19. Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int 1992;41:912–919.
20. Björck S, Mulec H, Johnsen SA, et al: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992;304:339–343.
21. Walker WG, Hermann J, Yin D, et al: Diuretics accelerate diabetic nephropathy in hypertensive insulin-dependent and non-insulin-dependent subjects. Trans Assoc Phys 1987;100P:305–315.
22. Anderson S: Renal hemodynamics of calcium antagonists in rats with reduced renal mass. Hypertension 1991;17:288–295.
23. Epstein M: Calcium antagonists and the kidney: implications for renal protection. Kidney Int 1992; 41(suppl 36):S66–S72.
24. Johnston CT, Clappison BH, Anderson WP, Yasujima M: Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol 1982;49:1401–1404.
25. Remuzzi A, Puntorieri S, Battaglia C, et al: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990;85: 541–549.
26. Björck S, Mulec H, Johnsen SA, et al: Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. Br Med J 1990;300:904–907.
27. Weidmann P, Boehlen LM, de Courten M, Ferrari P: Antihypertensive therapy in diabetic patients. J Human Hypertens 1992;6(suppl 2):S23–S36.
28. Weidmann P, Bohlen LM, de Courten M, Ferrari P: Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993;8: 582–584.
29. SAS Institute Inc: SAS User’s Guide: Statistics, Version 5. Cary, NC, SAS Institute, 1985.
30. Kleinbaum DG, Kupper LL, Muller KE: Applied Regression Analysis and Other Multivariable Methods, Chapter 14. Belmont, CA, Wadsworth Publishing, 1988.
31. Björck S, Nyberg G, Mulec H, et al: Beneficial efffects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986;293:471–474.
32. D’ Angelo A, Sartori L, Gambaro G, et al: Captopril in the treatment of hypertension in type I and type II diabetic patients. Postgrad Med J 1986; 62(suppl 1):69–72.
33. Zanella MT, Salgado BJL, Kohlmann O, Ribeiro AB: Converting enzyme inhibition: a therapeutical option for diabetic patients. Hypertension 1987;9:543.
34. Casado S, Carrasco MA, Arrieta FJ, Herrera JL: Effects of captopril in diabetic patients with different degrees of blood pressure and proteinuria. Postgrad Med J 1988;64(suppl 3):85.
35. Romero R, Sanmartl A, Salinas I, et al: Utilidad de los inhibidores de la enzima converiva de la angiotensina en el tratamiento de la nefropatia diabetica. Med Clin (Barcelona) 1988;90:494–496.
36. Valvo E, Bedogna P, Casagrande P, et al: Effects of captopril on systemic and renal haemodynamics in patients with diabetic nephropathy and renal insufficiency. Postgrad Med J 1988;64(suppl 3):89.
37. Doyle AE, Alford ME, Cooper M, et al: A comparison of the effects of blood pressure reduction with perin- dopril and nifedipine on micro-albuminuria in hypertensive and normotensive diabetics. J Hypertens 1989;7(suppl 6):S361.
38. Stornello M, Valvo EV, Scapellato L: Hemodynamic, renal, and humoral effects of the calcium entry blocker micardipine and converting enzyme inhibitor capto-pril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989;14:851–855.
39. Morelli E, Loon N, Meyer T, et al: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990;39:76–82.
40. Nieto J, Sanchez M, Lozano L, et al: Hypertension and proteinuria in diabetic patients. Long-term effect of captopril. Kidney Int 1990;37:1609–1610.
41. Slomowitz LA, Bergamo R, Grosvenor M, Kopple JD: Enalapril reduces albumin excretion in diabetic patients with low levels of microalbuminuria. Am J Nephrol 1990;10:457–462.
42. Apperloo AJ, de Zeeuw D, Sluiter HE, de Jong PE: Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. Br Med J 1991;303:821–824.
43. Bochicchio T, Ron O, Sandoval G, et al: Effect of captopril on proteinuria and renal hemodynamics in hypertensive type-II diabetic patients with nephropathy. Hypertension 1991;17:422.
44. Brusztyn M, Kobrin I, Fidel J, Ben-Ishay D: Improved kidney function with cilazapril in hypertensive type II diabetics with chronic renal failure. J Cardiovasc Pharmacol 1991;18:337–341.
45. Haisa S, Nforii T, Taka tori E, et al: Effects of angiotensin-converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive noninsulin-dependent diabetic patients with microalbuminuria. J Diabetic Complications 1991;5:162–164.
46. Holdaas H, Hartmann A, Lien MG, et al: Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetes with nephropathy. J Int Med 1991;229:163–170.
47. Marre M, Hallab M, Billiard A, et al: Small doses of ramipril do reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 1991;18(suppl):S165–S168.
48. Martello MA, Daccordi HA, Ferder LF, et al: Enalapril versus nifedipine in diabetic patients with hypertension and proteinuria (abst). Diabetes 1991;40:506A.
49. Mathiesen ER, Hommel E, Giese J, Parving HH: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 1991;303:81–87.
50. Silvani G, Bondi A, Nizzoli M, et al: Enalapril versus low protein diet: effects on microalbuminuria and kidney function in normotensive type I (insulin-dependent) diabetic patients with incipient nephropathy (abst). Diabetes 1991;40(suppl 1):441A.
51. Bochicchio T, Ron O, Sandoval G, et al: Antiproteinuric effect of captopril is associated with restoration of renal functional reserve (RFR) in NIDDM patients with nephropathy. J Hypertens 1992;10(suppl 4):S134.
52. Fioretto P, Frigato F, Velussi M, et al: Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992; 5:837–846.
53. Jungmann E, Haak T, Malanyn M, et al: Comparative study on renal effects of nitrendipine vs. enalapril in microalbuminuric patients with type 1 diabetes mellitus. J Hypertens 1992;10(suppl 4):S242.
54. Milagres R, Kohlmann O, Zanella MT, Ribeiro AB: Cilazapril reduces proteinuria in insulin dependent diabetes mellitus (IDDM) without change in renal hemodynamics. J Hypertens 1992;10(suppl 4):S276.
55. Romero R, Salinas I, Lucas A, et al: Comparative effects of captopril versus nifedipine on proteinuria and renal function. Diab Res Clin Pract 1992;17:191–198.
56. Romero R, Salinas I, Borras M, et al: Effects of angiotensin converting enzyme inhibitors in normotensive type 2 diabetic patients with microalbuminuria: a randomised study with control group. J Hypertens 1992;10(suppl 4):S109.
57. Tettamanti F, Zoppi A, Malmani GD, et al: Effects of ramipril and nitrendipine on proteinuria in hypertensive patients with albuminuric NIDDM. J Hypertens 1992;10(suppl 4):S102.
58. Hallab M, Gallois Y, Chatellier G, et al: Comparison of the effect of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. Br Med J 1993;306: 175–192.
59. Lacourciere Y, Nadeau A, Poirier L, Tancrede G: Captopril or conventional therapy in hypertensive type II diabetics. Hypertension 1993;21:786–794.
60. O’Donnell MJ, Rowe BR, Lawson N, et al: Comparison of the effect of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Hum Hypertens 1993; 7:333–339.
61. O’Donnell MJ, Rowe BR, Lawson N, et al: Placebo- controlled trial of lisinopril in normotensive diabetic patients with incipient nephropathy. J Hum Hypertens 1993;7:327–332.
62. Ravid M, Savin H, Jutrin I, et al: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 1993;118:577–581.
63. Slataper R, Vichnair N, Sadler R, Bakris GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Int Med 1993;153:973–980.
64. Bianchi S, Bigazzi R, Baldari G, Campese VM: Microalbuminuria in patients with essential hypertension. Am J Hypertens 1991;4:291–296.
65. Christensen CK, Mogensen CE: Antihypertensive treatment: long-term reversal of progression of albuminuria in incipient diabetic nephropathy. J Diabetic Complications 1987;1:45–52.
66. Janka HU, Weitz T, Bliimner E, et al: Hypertension and micro-albuminuria in diabetic patients taking in- dapamide. J Hypertens 1989;7(suppl 6):S316–S317.
67. Gambardella S, Frontoni S, Felici MG, et al: Efficacy of antihypertensive treatment with indapamide in patients with noninsulin-dependent diabetes and persistent microalbuminuria. Am J Cardiol 1990;65:46H–50H.
68. Tindall H, Urquhart S, Stickland M, Davies JA: Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. Curr Med Res Opin 1991;12:516–520.
69. Bauer JH, Reams GP, Hewett J, et al: A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 1992;20:443–457.
70. Mimran A, Insua A, Ribstein J, et al: Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 1988; 11:850–853.
71. Zusman RM: Renin and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. Kidney Int 1984;25:969–978.
72. Keane WF, Anderson S, Aurell M, et al: Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Ann Int Med 1989;111:503–516.
73. Demarie BK, Bakris GL: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Int Med 1990;113:987–988.
74. Anderson S: Renal hemodynamics of calcium antagonists in rats with reduced renal mass. Hypertension 1991;17:288–295.
75. Valentino VA, Wilson MD, Weart W, Bakris GL: A perspective on converting enzyme inhibitors and calcium antagonists in diabetic renal disease. Arch Intern Med 1991;151:2367–2372.
76. Loutzenhiser R, Epstein M: Renal micro vascular actions of calcium antagonists. J Am Soc Nephrol 1990; 41:487S–493S.
77. Bakris GL: Renal effects of calcium antagonists in diabetes mellitus. Am J Hypertens 1991;4:487S–493S.
78. Epstein M: Calcium antagonists and the kidney: implications for renal protection. Kidney Int 1992; 41(suppl 36):S66–S72.
79. Meyer TW, Morelli E, Loon N, et al: Converting enzyme inhibition and glomerular size selectivity in diabetic nephropathy. J Am Soc Nephrol 1990;l(suppl 2):564–568.
80. Ritz E, Orth S, Weinreich T, Wagner J: Systemic hypertension versus intraglomerular hypertension in progression. Kidney Int 1994;45:438–442.
81. Shultz PJ, Schorrer HE, Raij L: Effects of endothelium- derived relaxing factor and nitric oxide on rat mesangial cells. Am J Physiol 1990;258:F162–F167.
82. Koomans HA, Boer WH, Mees EJD: Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 1989;36:2–12.
83. Schardijn GHC, van Eps LWS: Beta-2-microglobulin: its significance in the evaluation of renal function. Kidney Int 1987;32:635–641.
84. Christensen CK, Lederballe Pederssen O, Mikkelsen E: Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta- adrenergic-blocking drugs. Clin Pharmacol Ther 1982; 32:572–576.
85. Bohlen LM, Weidmann P, de Courten M, et al: Antihypertensive drug effects on left ventricular hypertrophy: meta-analysis considering duration of treatment. Abstract of the 15th Scientific Meeting of the International Society of Hypertension, Melbourne, March 1994.
86. Weidmann P, Boehlen LM, de Courten M: Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993;125:1498–1513.
87. Bergemann R, Betzin J, Nawrath T, Weidmann P: Ver- besserte Glukoseeinstellung und Albuminurie bei Di-abetikaern unter ACE-Hemmer-Behandlung: Eine Metaanalyse publizierter Studein aus den Jahren 1985 bis 1990. Schweiz Med Wochenschr 1993;122:1369–1376.
88. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Part 2: short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;i:827–838.
89. Klein R, Moss SE, Klein BEK, DeMets DL: Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med 1989;149:266–272.
90. Warram JH, Laffel LMB, Valsania P, et al: Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991;151:1350–1356.
91. Parving HH: The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J Hypertens 1990;8(suppl 7):S187–S191.
92. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.